Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current HIV/AIDS Reports
Published in: Current HIV/AIDS Reports 1/2012

01-03-2012 | The Science of HIV (AL Landay, Section Editor)

Gene Array Studies in HIV-1 Infection

Authors: Rajeev Mehla, Velpandi Ayyavoo

Published in: Current HIV/AIDS Reports | Issue 1/2012

Login to get access

Abstract

HIV-1–infected individuals exhibit remarkable variation in the onset of disease. Virus replication and disease progression depend on host cellular transcription and gene regulation in virus-specific target cells. Both viral and host factors are implicated in this differential regulation. Gene arrays and transcriptome analyses might shed light on why some infected individuals remain asymptomatic while others progress rapidly to AIDS. Here we review developments in HIV research using gene array technologies and the unifying concepts that have emerged from these studies. Gene set enrichment analysis has revealed gene signatures linked to disease progression involving pathways related to metabolism, apoptosis, cell-cycle dysregulation, and T-cell signaling. Macrophages contain anti-apoptotic signatures. Also, HIV-1 regulates previously under-emphasized cholesterol biosynthesis and energy production pathways. Notably, cellular pathways linked to a subset of HIV-infected individuals known as non-progressors contribute to survival and anti-viral responses.
Literature
1.
• Giri MS, Nebozhyn M, Showe L, et al. Microarray data on gene modulation by HIV-1 in immune cells: 2000–2006. J Leukoc Biol. 2006;80:1031–43. The authors have analyzed the gene expression studies and analytical approaches used in the studies prior to 2006. PubMedCrossRef
2.
Doniger SW, Salomonis N, Dahlquist KD, et al. MAPPFinder: using Gene Ontology and GenMAPP to create a global gene-expression profile from microarray data. Genome Biol. 2003;4:R7.PubMedCrossRef
3.
t’ Wout AB. Gene expression profiling of HIV-1 infection using cDNA microarrays. Methods Mol Biol. 2005;304:455–9.
4.
Heath SL, Sabbaj S, Bansal A, et al. CD8 T-cell proliferative capacity is compromised in primary HIV-1 infection. J Acquir Immune Defic Syndr. 2011;56:213–21.PubMedCrossRef
5.
Richard J, Sindhu S, Pham TN, et al. HIV-1 Vpr up-regulates expression of ligands for the activating NKG2D receptor and promotes NK cell-mediated killing. Blood. 2010;115:1354–63.PubMedCrossRef
6.
Yadav A, Collman RG. CNS inflammation and macrophage/microglial biology associated with HIV-1 infection. J Neuroimmune Pharmacol. 2009;4:430–47.PubMedCrossRef
7.
Kottilil S, Shin K, Jackson JO, et al. Innate immune dysfunction in HIV infection: effect of HIV envelope-NK cell interactions. J Immunol. 2006;176:1107–14.PubMed
8.
9.
Betts MR, Nason MC, West SM, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood. 2006;107:4781–9.PubMedCrossRef
10.
• Wu JQ, Dwyer DE, Dyer WB, et al. Genome-wide analysis of primary CD4+ and CD8+ T cell transcriptomes shows evidence for a network of enriched pathways associated with HIV disease. Retrovirology. 2011;8:18. This study compared the insights from HIV-infected long-term non-progressors. PubMedCrossRef
11.
Giri MS, Nebozyhn M, Raymond A, et al. Circulating monocytes in HIV-1-infected viremic subjects exhibit an antiapoptosis gene signature and virus- and host-mediated apoptosis resistance. J Immunol. 2009;182:4459–70.PubMedCrossRef
12.
• Van den BR, Florence E, Vlieghe E, et al. Transcriptome analysis of monocyte-HIV interactions. Retrovirology. 2010;7:53. This is an important study where authors found gene correlates of HIV disease progression (eg, NAMPT) and therapy-associated complications (eg, CCL1 and CYP2C19). CrossRef
13.
Majumder B, Venkatachari NJ, Schafer EA, et al. Dendritic cells infected with vpr-positive human immunodeficiency virus type 1 induce CD8+ T-cell apoptosis via upregulation of tumor necrosis factor alpha. J Virol. 2007;81:7388–99.PubMedCrossRef
14.
Gougeon ML. Apoptosis as an HIV strategy to escape immune attack. Nat Rev Immunol. 2003;3:392–404.PubMedCrossRef
15.
Cummins NW, Badley AD. Mechanisms of HIV-associated lymphocyte apoptosis: 2010. Cell Death Dis. 2010;1:e99.PubMedCrossRef
16.
Malim MH, Emerman M. HIV-1 accessory proteins–ensuring viral survival in a hostile environment. Cell Host Microbe. 2008;3:388–98.PubMedCrossRef
17.
Corbeil J, Sheeter D, Genini D, et al. Temporal gene regulation during HIV-1 infection of human CD4+ T cells. Genome Res. 2001;11:1198–204.PubMedCrossRef
18.
t’ Wout AB, Lehrman GK, Mikheeva SA, et al. Cellular gene expression upon human immunodeficiency virus type 1 infection of CD4+−T-cell lines. J Virol. 2003;77:1392–402.CrossRef
19.
Kartvelishvili A, Lesner A, Szponar M, et al. Microarray analysis of differentially expressed genes in cells resistant to HIV-1. Immunol Lett. 2004;93:79–86.PubMedCrossRef
20.
Woelk CH, Ottones F, Plotkin CR, et al. Interferon gene expression following HIV type 1 infection of monocyte-derived macrophages. AIDS Res Hum Retroviruses. 2004;20:1210–22.PubMedCrossRef
21.
Coberley CR, Kohler JJ, Brown JN, et al. Impact on genetic networks in human macrophages by a CCR5 strain of human immunodeficiency virus type 1. J Virol. 2004;78:11477–86.PubMedCrossRef
22.
Wen W, Chen S, Cao Y, et al. HIV-1 infection initiates changes in the expression of a wide array of genes in U937 promonocytes and HUT78 T cells. Virus Res. 2005;113:26–35.PubMedCrossRef
23.
Solis M, Wilkinson P, Romieu R, et al. Gene expression profiling of the host response to HIV-1 B, C, or A/E infection in monocyte-derived dendritic cells. Virology. 2006;352:86–99.PubMedCrossRef
24.
Blankson JN, Bailey JR, Thayil S, et al. Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J Virol. 2007;81:2508–18.PubMedCrossRef
25.
Blankson JN. Effector mechanisms in HIV-1 infected elite controllers: highly active immune responses? Antiviral Res. 2010;85:295–302.PubMedCrossRef
26.
Baker BM, Block BL, Rothchild AC, et al. Elite control of HIV infection: implications for vaccine design. Expert Opin Biol Ther. 2009;9:55–69.PubMedCrossRef
27.
Saez-Cirion A, Pancino G, Sinet M, et al. HIV controllers: how do they tame the virus? Trends Immunol. 2007;28:532–40.PubMedCrossRef
28.
Hubert JB, Burgard M, Dussaix E, et al. Natural history of serum HIV-1 RNA levels in 330 patients with a known date of infection. The SEROCO Study Group. AIDS. 2000;14:123–31.PubMedCrossRef
29.
Bryant PA, Smyth GK, Robins-Browne R, et al. Detection of gene expression in an individual cell type within a cell mixture using microarray analysis. PLoS One. 2009;4:e4427.PubMedCrossRef
30.
McLaren PJ, Mayne M, Rosser S, et al. Antigen-specific gene expression profiles of peripheral blood mononuclear cells do not reflect those of T-lymphocyte subsets. Clin Diagn Lab Immunol. 2004;11:977–82.PubMed
31.
Montano M, Rarick M, Sebastiani P, et al. Gene-expression profiling of HIV-1 infection and perinatal transmission in Botswana. Genes Immun. 2006;7:298–309.PubMedCrossRef
32.
Boutboul F, Puthier D, Appay V, et al. Modulation of interleukin-7 receptor expression characterizes differentiation of CD8 T cells specific for HIV, EBV and CMV. AIDS. 2005;19:1981–6.PubMedCrossRef
33.
Salgado M, Lopez-Romero P, Callejas S, et al. Characterization of host genetic expression patterns in HIV-infected individuals with divergent disease progression. Virology. 2011;411:103–12.PubMedCrossRef
34.
• Vigneault F, Woods M, Buzon MJ, et al. Transcriptional profiling of CD4 T cells identifies distinct subgroups of HIV-1 elite controllers. J Virol. 2011;85:3015–19. This is an important study where the authors for the first time report two subgroups of elite controllers based on their gene profile. One of the ECs subgroup is closely related to uninfected controls, in contrast to the other subgroup which is more related to HIV-infected treated patients. This has implications in the development of effective therapy against HIV. PubMedCrossRef
35.
Williams SA, Greene WC. Regulation of HIV-1 latency by T-cell activation. Cytokine. 2007;39:63–74.PubMedCrossRef
36.
Chun TW, Justement JS, Lempicki RA, et al. Gene expression and viral prodution in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals. Proc Natl Acad Sci. 2003;100:1908–13.PubMedCrossRef
37.
Munier S, Delcroix-Genete D, Carthagena L, et al. Characterization of two candidate genes, NCoA3 and IRF8, potentially involved in the control of HIV-1 latency. Retrovirology. 2005;2:73.PubMedCrossRef
38.
Lau B, Sharrett AR, Kingsley LA, et al. C-reactive protein is a marker for human immunodeficiency virus disease progression. Arch Intern Med. 2006;166:64–70.PubMedCrossRef
39.
Heggelund L, Flo T, Berg K, et al. Soluble toll-like receptor 2 in HIV infection: association with disease progression. AIDS. 2004;18:2437–9.PubMed
40.
Fernandes AP, Goncalves MA, Zavanella RB, et al. HLA markers associated with progression to AIDS are also associated with susceptibility to cytomegalovirus retinitis. AIDS. 2003;17:2133–6.PubMedCrossRef
41.
Carbone J, Sarmiento E, Rodriguez-Molina JJ, et al. Immunoglobulin levels and prediction of progression to AIDS in HIV-infected injection drug users. AIDS Patient Care STDS. 2004;18:685–6.PubMedCrossRef
42.
Kiprov DD, Anderson RE, Morand PR, et al. Antilymphocyte antibodies and seropositivity for retroviruses in groups at high risk for AIDS. N Engl J Med. 1985;312:1517.PubMed
43.
Lambin P, Lefrere JJ, Doinel C, et al. Neopterin and beta 2-microglobulin in serum of HIV-seropositive subjects during a two-year follow-up. Clin Chem. 1988;34:1367–8.PubMed
44.
Mallewa JE, Wilkins E, Vilar J, et al. HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options. J Antimicrob Chemother. 2008;62:648–60.PubMedCrossRef
45.
Nagy GS, Tsiodras S, Martin LD, et al. Human immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptin. Clin Infect Dis. 2003;36:795–802.PubMedCrossRef
46.
Fiorenza CG, Chou SH, Mantzoros CS. Lipodystrophy: pathophysiology and advances in treatment. Nat Rev Endocrinol. 2011;7:137–50.PubMedCrossRef
47.
Pacenti M, Barzon L, Favaretto F, et al. Microarray analysis during adipogenesis identifies new genes altered by antiretroviral drugs. AIDS. 2006;20:1691–705.PubMedCrossRef
48.
Waring JF, Ciurlionis R, Marsh K, et al. Identification of proteasome gene regulation in a rat model for HIV protease inhibitor-induced hyperlipidemia. Arch Toxicol. 2010;84:263–70.PubMedCrossRef
49.
Ellinger-Ziegelbauer H, Adler M, Amberg A, et al. The enhanced value of combining conventional and “omics” analyses in early assessment of drug-induced hepatobiliary injury. Toxicol Appl Pharmacol. 2011;252:97–111.PubMedCrossRef
50.
Suter L, Schroeder S, Meyer K, et al. EU Framework 6 Project: Predictive Toxicology PredTox-overview and outcome. Toxicol Appl Pharmacol. 2011;252:73–84.PubMedCrossRef
51.
Bolt HM, Marchan R. Hengstler JG Gene array screening for identification of drugs with low levels of adverse side effects. Arch Toxicol. 2010;84:253–4.PubMedCrossRef
52.
Tavel JA, Babiker A, Fox L, et al. Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study. PLoS One. 2010;5:e9334.PubMedCrossRef
53.
Motomura K, Toyoda N, Oishi K, et al. Identification of a host gene subset related to disease prognosis of HIV-1 infected individuals. Int Immunopharmacol. 2004;4:1829–36.PubMedCrossRef
54.
Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12:1365–71.PubMedCrossRef
55.
Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011;203:780–90.PubMedCrossRef
56.
Boulware DR, Hullsiek KH, Puronen CE, et al. Higher Levels of CRP, D-dimer, IL-6, and Hyaluronic Acid Before Initiation of Antiretroviral Therapy ART Are Associated With Increased Risk of AIDS or Death. J Infect Dis. 2011;203:1637–46.PubMedCrossRef
57.
• Rotger M, Dalmau J, Rauch A, et al. Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. J Clin Invest. 2011;121:2391–400. This is the first study that emphasized the rarely reported in literature HIV-1 phenotypes and highlighted the importance of using simian models of HIV infection. PubMedCrossRef
58.
Miller RC, Schlaepfer E, Baenziger S, et al. HIV interferes with SOCS-1 and −3 expression levels driving immune activation. Eur J Immunol. 2011;41:1058–69.PubMedCrossRef
59.
Whyte CS, Bishop ET, Ruckerl D, et al. Suppressor of cytokine signaling SOCS1 is a key determinant of differential macrophage activation and function. J Leukoc Biol. 2011. doi:10.​1189/​jib.​1110644.
60.
Nakagawa R, Naka T, Tsutsui H, et al. SOCS-1 participates in negative regulation of LPS responses. Immunity. 2002;17:677–87.PubMedCrossRef
61.
Marconi VC, Grandits G, Okulicz JF, et al. Cumulative Viral Load and Virologic Decay Patterns after Antiretroviral Therapy in HIV-Infected Subjects Influence CD4 Recovery and AIDS. PLoS One. 2011;6:e17956.PubMedCrossRef
62.
Moir S, Donoghue ET, Pickeral OK, et al. Continuous flow leukapheresis induces expression of stress genes in lymphocytes: impact on microarray analyses. Blood. 2003;102:3852–3.PubMedCrossRef
63.
Wu JQ, Wang B, Saksena NK. Transitory viremic surges in a human immunodeficiency virus-positive elite controller can shift the cellular transcriptome profile: a word of caution for microarray studies. J Virol. 2008;82:10326–7.PubMedCrossRef
64.
Smyth G.K. Limma: linear models for microarray data. In: Informatics and computational biology solutions using R and Bioconductor. New York: Springer; 2011. pp. 397–420.
65.
Benjamini Y, Hochberg Y. Controlling the false discovery rate: a proacital and powerful approach to multiple testing. J R Statist Soc B. 1995;57:289.
66.
67.
Ferre AL, Hunt PW, Critchfield JW, et al. Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. Blood. 2009;113:3978–89.PubMedCrossRef
68.
Pereyra F, Addo MM, Kaufmann DE, et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis. 2008;197:563–71.PubMedCrossRef
69.
Wu JQ, Dwyer DE, Dyer WB, et al. Transcriptional profiles in CD8+ T cells from HIV+ progressors on HAART are characterized by coordinated up-regulation of oxidative phosphorylation enzymes and interferon responses. Virology. 2008;380:124–35.PubMedCrossRef
70.
Geiss GK, Bumgarner RE, An MC, et al. Large-scale monitoring of host cell gene expression during HIV-1 infection using cDNA microarrays. Virology. 2000;266:8–16.PubMedCrossRef
Metadata
Title
Gene Array Studies in HIV-1 Infection
Authors
Rajeev Mehla
Velpandi Ayyavoo
Publication date
01-03-2012
Publisher
Current Science Inc.
Published in
Current HIV/AIDS Reports / Issue 1/2012
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-011-0100-x

Other articles of this Issue 1/2012

Current HIV/AIDS Reports 1/2012 Go to the issue

The Science of HIV (AL Landay, Section Editor)

HIV: Inflammation and Bone

The Science of HIV (AL Landay, Section Editor)

Role of PD-1 in HIV Pathogenesis and as Target for Therapy

The Science of HIV (AL Landay, Section Editor)

HIV Reservoirs and Strategies for Eradication

The Science of HIV (AL Landay, Section Editor)

New Tools for Quantifying HIV-1 Reservoirs: Plasma RNA Single Copy Assays and Beyond

The Science of HIV (AL Landay, Section Editor)

Human Microbiome and HIV/AIDS

The Science of HIV (AL Landay, Section Editor)

The HIV-1 Env Protein: A Coat of Many Colors
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits